• BRVE share price: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

  • BRVE stock price change: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

  • BRVE market open/close: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

Key terms

About BRVE

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

  • BRVE market cap: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

Smart score

Latest BRVE news

No recent TipRanks articles are available for BRVE

No recent press releases are available for BRVE

BRVE Financials

1-year income & revenue

  • BRVE total revenue: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

  • BRVE net income: temporarily unavailable. We are sorry, but this information is temporarily unavailable.

  • BRVE earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

BRVE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BRVE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    BRVE's competitors are included in the Health Technology sector and Biotechnology group

  • BRVE market cap: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

Latest investing news